Clinical trials: Cholera
Cholera (Disorder)
Ondansetron to Prevent Oral Rehydration Failure in Children With Cholera
This Phase IIa randomized controlled trial will evaluate whether a single oral dose of ondansetron can reduce oral rehydration failure in children and adolescents with suspected or confirmed cholera and active vomiting.
- Trial name
- NCT07795060
- Testing
- Ondansetron, Standard Cholera Care
- Where
- Republic of the Congo
- Volunteers
- 120 people
- Sponsor
- Public Interest Science Center
Cholera Vaccination Reaction
Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers
Cholera is a serious diarrheal disease that can be fatal within hours of onset. The current available cholera vaccines to prevent the disease are not very effective.
- Trial name
- PanChol (NCT07107516)
- Testing
- PanChol
- Where
- Zambia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Typhoid and/or Cholera Vaccination
CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever and cholera affect the normal immune system and bacteria in the intestine.
- Trial name
- NCT03705585
- Testing
- Vivotif Typhoid Oral Vaccine, Vaxchora
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Cholera
Single Dose Azithromycin to Prevent Cholera in Children
This study aims to determine whether single-dose azithromycin is effective in preventing cholera in children who are at extremely high risk of infection.
- Trial name
- NCT04326478
- Testing
- Azithromycin
- Where
- Bangladesh
- Volunteers
- 2,475 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cholera, Methodology Study
Cholera Control by Case-area Targeted Interventions (CATIs)
To evaluate the effectiveness of the CATI approach among household contacts in the reduction of cumulative incidence of cholera and explore the genome analysis and immune response of V.
- Trial name
- NCT07685574
- Testing
- Cholvax
- Where
- Bangladesh
- Volunteers
- 68,400 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
Cholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated.
- Trial name
- NCT06193408
- Testing
- VR-AD-1005
- Where
- Bangladesh
- Volunteers
- 150 people
- Sponsor
- Hunazine Biotech S.L.
Diarrhea Infectious, Cholera
Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)
The findings from previous recent randomized controlled trials of The Cholera Hospital Based Intervention for 7 Days (CHoBI7) demonstrated that this intervention was effective in significantly reducing symptomatic cholera…
- Trial name
- CHoBI7 (NCT06498817)
- Testing
- Standard Recommendation, CHoBI7 Scale-Up Program
- Where
- Bangladesh
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhea, Cholera
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea
Diarrhea remains a leading killer of children in need of better treatments.
- Trial name
- ORS (NCT05814042)
- Testing
- Current standard control ORS (oral rehydration solution)
- Where
- Bangladesh
- Volunteers
- 396 people
- Sponsor
- University of Florida
Cholera
Vaccine- and Infection-derived Correlates of Protection for Cholera
Background: Vibrio cholerae causes millions of cholera cases and thousands of deaths annually. Vaccines are in short supply. There is no agreement on how to introduce new vaccines or evaluate their effectiveness, and the lack of…
- Trial name
- CoP (NCT06455852)
- Testing
- oral cholera vaccine or typhoid conjugate vaccine
- Where
- Bangladesh
- Volunteers
- 1,221 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cholera Vaccination
Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children
This phase II study is intended to determine the immunogenicity and safety of single dose and two doses of OSP:rTTHc cholera conjugate vaccine (CCV) with or without alum adjuvant.
- Trial name
- NCT07509047
- Testing
- OSP:rTTHc CCV 25 ㎍ with Aluminum phosphate, OSP:rTTHc CCV 25 ㎍ without Aluminum phosphate, Euvichol®-Plus
- Where
- Kenya
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera Vaccination Reaction
Safety and Immunogenicity Study of the DuoChol Oral Cholera Vaccine in Healthy Participants
The goal of this phase I, open-label, randomized, active-controlled Trial is to evaluate the safety and immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old healthy participants in Sweden.
- Trial name
- DuoChol (NCT07270796)
- Testing
- DuoChol, Dukoral®
- Where
- Sweden
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera Vaccination
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
Background: Despite efforts to control cholera, outbreaks continue to occur in Kenya. Oral cholera vaccines (OCVs) are a critical tool in cholera prevention strategies.
- Trial name
- NCT07487077
- Testing
- Euvichol-S Oral Cholera Vaccine
- Where
- Kenya
- Volunteers
- 1,071 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Cholera
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
The primary objective of this study is to evaluate the antibody response to the cholera vaccine, Vaxchora®, in healthy subjects.
- Trial name
- NCT03251495
- Testing
- Vaxchora
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Emory University
Cholera Vaccination
Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus
This Phase I/III clinical trial is intended to establish the immunogenicity and safety profile of Biovac OCV-S compared to available WHO pre-qualified vaccine Euvichol®-Plus in healthy adults and children and in adult people…
- Trial name
- NCT07304284
- Testing
- Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine), Active Comparator, Euvichol®-Plus
- Where
- 5 sites in South Africa
- Volunteers
- 2,824 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Cholera, Water-Related Diseases
Preventative Intervention for Cholera for 7 Days
The first objective of our study is to develop a theory-driven evidence-based targeted water, sanitation, and hygiene (WASH) intervention for household members of diarrhea patients in South Kivu, Democratic Republic of the Congo…
- Conditions
- Cholera, Water-Related Diseases, Diarrhea Infectious
- Trial name
- PICHA-7 (NCT05166850)
- Testing
- PICHA7 mHealth program, Standard Arm
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 2,900 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera, Diarrhea
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
Objective: The investigators objective is to develop and evaluate the effectiveness of a case area targeted water, sanitation, and hygiene (WASH) intervention in reducing cholera infections and increasing sustained WASH behaviors…
- Trial name
- NCT06003816
- Testing
- Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) CATI, Standard message
- Where
- 2 sites in Bangladesh
- Volunteers
- 3,140 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cholera
Simulation Based Training In Medical Students
Transferring classroom learning to real-life situations is a challenge. Tabletop simulation exercises offer a low-cost and context-specific approach for educating students on appropriate responses during health emergencies.
- Trial name
- NCT06929312
- Testing
- Tabletop simulation based teaching, conventional class room teaching
- Where
- Pakistan
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- CMH Lahore Medical College and Institute of Dentistry
Shock Hypovolemic, Shock, Septic
Management of Shock in Children With SAM or Severe Underweight and Diarrhea
Diarrhea is one of the leading causes of under-five childhood mortality and accounts for 8% of 5.4 million global under-5 deaths.
- Conditions
- Shock Hypovolemic, Shock, Septic, Blood Transfusion, Adrenaline
- Trial name
- NCT04750070
- Testing
- Blood and Dopamine, Blood and adrenaline
- Where
- Bangladesh
- Volunteers
- 135 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Cholera Vaccination Reaction
Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults
This Phase I, first-in-human study is intended to primarily determine the safety of the dose range with or without Aluminum phosphate adjuvant expected to be needed for later clinical studies, to determine the nature of adverse…
- Trial name
- NCT05559983
- Testing
- OSP:rTTHc Cholera Conjugate Vaccine Cohort A, OSP:rTTHc Cholera Conjugate Vaccine with Aluminum phosphate adjuvant Cohort A, OSP:rTTHc Cholera Conjugate Vaccine Cohort B
- Where
- 3 sites in South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Vaccine-Preventable Diseases, Typhoid Fever
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
The goal of this clinical trial is to explore the coadministration of oral typhoid fever (Vivotif®) and cholera (Dukoral®) vaccines in healthy volunteers aged 18-65 years.
- Conditions
- Vaccine-Preventable Diseases, Typhoid Fever, Cholera
- Trial name
- NCT06104345
- Testing
- Oral typhoid fever vaccine, Oral cholera vaccine
- Where
- Finland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital